Genome-wide association studies to advance our understanding of critical cell types and pathways in rheumatoid arthritis: Recent findings and challenges

Current Opinion in Rheumatology

Volumn 26, Issue 1, 2014, Pages 85-92

  Diogo, Dorothée ^a,b,c   Okada, Yukinori ^a,b,c   Plenge, Robert M ^a,b,c,d  

^a Division of Rheumatology   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CD4+ memory T cells; genome wide association studies; JAK STAT signaling pathway; NF B signaling pathway; regulatory T cells; rheumatoid arthritis INTRODUCTI

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; JANUS KINASE; STAT PROTEIN; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; CD4+ T LYMPHOCYTE; DISEASE PREDISPOSITION; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TRANSDUCER;

ARTHRITIS, RHEUMATOID; CD4-POSITIVE T-LYMPHOCYTES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; JANUS KINASES; MAJOR HISTOCOMPATIBILITY COMPLEX; NF-KAPPA B; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84890162458     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000012     Document Type: Review

References (98)

1. Visscher PM, Brown MA, McCarthy MI, et al. Five years of GWAS discovery. Am J Hum Genet 2012; 90:7-24.
2. Parkes M, Cortes A, van Heel DA, et al. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013; 14:661-673.
3. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther 2011; 13:101.
4. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013; 12:581-594.
5. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30:1205-1213.
6. Lee HS, Lee AT, Criswell LA, et al. Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus. Mol Med 2008; 14:293-300.
7. Vignal C, Bansal AT, Balding DJ, et al. Genetic association of the major histocompatibility complex with rheumatoid arthritis implicates two non-DRB1 loci. Arthritis Rheum 2009; 60:53-62.
8. Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44:291-296.
9. Eyre S, Bowes J, Diogo D, et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012; 44:1336-1340.
10. Raychaudhuri S, Plenge RM, Rossin EJ, et al. Identifying relationships among genomic disease regions: Predicting genes at pathogenic SNP associations and rare deletions. PLoS Genet 2009; 5:e1000534.
11. Barton A, Eyre S, Ke X, et al. Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Hum Mol Genet 2009; 18:2518-2522.
12. Gregersen PK, Amos CI, Lee AT, et al. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet 2009; 41:820-823.
13. Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis: A genomewide study. N Engl J Med 2007; 357:1199- 1209.
14. Raychaudhuri S, Remmers EF, Lee AT, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008; 40:1216- 1223.
15. Raychaudhuri S, Thomson BP, Remmers EF, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 2009; 41:1313-1318.
16. Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42:508-514.
17. Diogo D, Kurreeman F, Stahl EA, et al. Rare, low-frequency, and common variants in the protein-coding sequence of biological candidate genes from GWASs contribute to risk of rheumatoid arthritis. Am J Hum Genet 2013; 92:15-27.
18. Stahl EA, Wegmann D, Trynka G, et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet 2012; 44:483-489.
19. Neogi T, Aletaha D, Silman AJ, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum 2010; 62:2582-2591.
20. Ding B, Padyukov L, Lundstrom E, et al. Different patterns of associations with anticitrullinated protein antibody-positive and anticitrullinated protein antibody- negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum 2009; 60:30-38.
21. Irigoyen P, Lee AT, Wener MH, et al. Regulation of anticyclic citrullinated peptide antibodies in rheumatoid arthritis: Contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005; 52:3813-3818.
22. van der Woude D, Houwing-Duistermaat JJ, Toes RE, et al. Quantitative heritability of anticitrullinated protein antibody-positive and anticitrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009; 60:916-923.
23. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH, et al. Association of HLA-DR3 with anticyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum 2005; 52:3058-3062.
24. Mackie SL, Taylor JC, Martin SG, et al. A spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: Stratification by autoantibody status in a large UK population. Genes Immun 2012; 13:120-128.
25. Viatte S, Plant D, Bowes J, et al. Genetic markers of rheumatoid arthritis susceptibility in anticitrullinated peptide antibody negative patients. Ann Rheum Dis 2012; 71:1984-1990.
26. Seddighzadeh M, Gonzalez A, Ding B, et al. Variants within STAT genes reveal association with anticitrullinated protein antibody-negative rheumatoid arthritis in 2 European populations. J Rheumatol 2012; 39:1509-1516.
27. Padyukov L, Seielstad M, Ong RT, et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011; 70:259-265.
28. Daha NA, Lie BA, Trouw LA, et al. Novel genetic association of the VTCN1 region with rheumatoid arthritis. Ann Rheum Dis 2012; 71:567-571.
29. Takata Y, Inoue H, Sato A, et al. Replication of reported genetic associations of PADI4, FCRL3, SLC22A4 and RUNX1 genes with rheumatoid arthritis: Results of an independent Japanese population and evidence from metaanalysis of East Asian studies. J Hum Genet 2008; 53:163-173.
30. Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34:395-402.
31. Okada Y, Terao C, Ikari K, et al. Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet 2012; 44:511-516.
32. Kang CP, Lee HS, Ju H, et al. A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis Rheum 2006; 54:90-96.
33. Ikari K, Kuwahara M, Nakamura T, et al. Association between PADI4 and rheumatoid arthritis: A replication study. Arthritis Rheum 2005; 52:3054- 3057.
34. Freudenberg J, Lee HS, Han BG, et al. Genome-wide association study of rheumatoid arthritis in Koreans: Population-specific loci as well as overlap with European susceptibility loci. Arthritis Rheum 2011; 63:884-893.
35. Tanikawa C, Ueda K, Nakagawa H, et al. Regulation of protein Citrullination through p53/PADI4 network in DNA damage response. Cancer Res 2009; 69:8761-8769.
36. Hughes LB, Reynolds RJ, Brown EE, et al. Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. Arthritis Rheum 2010; 62:3547-3553.
37. Kelley JM, Hughes LB, Malik A, et al. Genetic variants of STAT4 associated with rheumatoid arthritis in persons of Asian and European ancestry do not replicate in African Americans. Ann Rheum Dis 2010; 69:625-626.
38. Kurreeman F, Liao K, Chibnik L, et al. Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multiethnic cohort derived from electronic health records. Am J Hum Genet 2011; 88:57-69.
39. Perkins EA, Landis D, Causey ZL, et al. Association of single-nucleotide polymorphisms in CCR6, TAGAP, and TNFAIP3 with rheumatoid arthritis in African Americans. Arthritis Rheum 2012; 64:1355-1358.
40. Terao C, Yamada R, Ohmura K, et al. The human AIRE gene at chromosome 21q22 is a genetic determinant for the predisposition to rheumatoid arthritis in Japanese population. Hum Mol Genet 2011; 20:2680-2685.
41. Wipke BT, Allen PM. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol 2001; 167:1601-1608.
42. Pap T, Muller-Ladner U, Gay RE, et al. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000; 2:361-367.
43. Lefevre S, Knedla A, Tennie C, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 2009; 15:1414-1420.
44. Lee DM, Friend DS, Gurish MF, et al. Mast cells: A cellular link between autoantibodies and inflammatory arthritis. Science 2002; 297:1689-1692.
45. Kinne RW, Brauer R, Stuhlmuller B, et al. Macrophages in rheumatoid arthritis. Arthritis Res 2000; 2:189-202.
46. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423:356-361.
47. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327:580-583.
48. McCarroll SA, Huett A, Kuballa P, et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat Genet 2008; 40:1107-1112.
49. Dendrou CA, Plagnol V, Fung E, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009; 41:1011-1015.
50. Hu X, Kim H, Stahl E, et al. Integrating autoimmune risk loci with geneexpression data identifies specific pathogenic immune cell subsets. Am J Hum Genet 2011; 89:496-506.
51. Trynka G, Sandor C, Han B, et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet 2013; 45:124- 130.
52. Zhou L, Chong MM, Littman DR. Plasticity of CD4 T cell lineage differentiation. Immunity 2009; 30:646-655.
53. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277-285.
54. Dardalhon V, Korn T, Kuchroo VK, et al. Role of Th1 and Th17 cells in organspecific autoimmunity. J Autoimmun 2008; 31:252-256.
55. Wang W, Shao S, Jiao Z, et al. The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis. Rheumatol Int 2012; 32:887-893.
56. Samson M, Audia S, Janikashvili N, et al. Inhibition of IL-6 function corrects Th17/Treg imbalance in rheumatoid arthritis patients. Arthritis Rheum 2012; 64:2499-24503.
57. Criswell LA. Gene discovery in rheumatoid arthritis highlights the CD40/NFkappaB signaling pathway in disease pathogenesis. Immunol Rev 2010; 233:55-61.
58. Rossin EJ, Lage K, Raychaudhuri S, et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet 2011; 7:e1001273.
59. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365:2205-2219.
60. Berner B, Wolf G, Hummel KM, et al. Increased expression of CD40 ligand (CD154) on CD4 T cells as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis 2000; 59:190-195.
61. Durie FH, Fava RA, Foy TM, et al. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261:1328- 1330.
62. Kyburz D, Carson DA, Corr M. The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K/BxN mouse model of rheumatoid arthritis. Arthritis Rheum 2000; 43:2571-2577.
63. Li G, Diogo D, Wu D, et al. Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathway. PLoS Genet 2013; 9:e1003487.
64. Mauri C, Mars LT, Londei M. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nat Med 2000; 6:673-679.
65. Senior K. Anti-CD40 allays rheumatoid arthritis in mice. Lancet 2000; 355:2054.
66. Zheng X, Suzuki M, Zhang X, et al. RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Ther 2010; 12:R13.
67. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012; 36:542-550.
68. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121:3375-3383.
69. Garber K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol 2011; 29:467-468.
70. Garber K. Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nat Biotechnol 2013; 31:3-4.
71. Arechiga AF, Habib T, He Y, et al. Cutting edge: The PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol 2009; 182:3343-3347.
72. Couturier N, Bucciarelli F, Nurtdinov RN, et al. Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain 2011; 134:693-703.
73. Ferreira RC, Freitag DF, Cutler AJ, et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet 2013; 9:e1003444.
74. Kochi Y, Okada Y, Suzuki A, et al. A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 2010; 42:515-519.
75. Rieck M, Arechiga A, Onengut-Gumuscu S, et al. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J Immunol 2007; 179:4704-4710.
76. Komiyama H, Aoki A, Tanaka S, et al. Alu-derived cis-element regulates tumorigenesis-dependent gastric expression of GASDERMIN B (GSDMB). Genes Genet Syst 2010; 85:75-83.
77. Saeki N, Usui T, Aoyagi K, et al. Distinctive expression and function of four GSDM family genes (GSDMA-D) in normal and malignant upper gastrointestinal epithelium. Genes Chromosomes Cancer 2009; 48:261-271.
78. Carreras-Sureda A, Cantero-Recasens G, Rubio-Moscardo F, et al. ORMDL3 modulates store-operated calcium entry and lymphocyte activation. Hum Mol Genet 2013; 22:519-530.
79. Hsu KJ, Turvey SE. Functional analysis of the impact of ORMDL3 expression on inflammation and activation of the unfolded protein response in human airway epithelial cells. Allergy Asthma Clin Immunol 2013; 9:4.
80. Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013; 9:141-153.
81. Bell CG, Finer S, Lindgren CM, et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One 2010; 5:e14040.
82. Adrianto I, Wen F, Templeton A, et al. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet 2011; 43:253-258.
83. Cowper-Sal lari R, Zhang X, Wright JB, et al. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet 2012; 44:1191-1198.
84. Karczewski KJ, Dudley JT, Kukurba KR, et al. Systematic functional regulatory assessment of disease-associated variants. Proc Natl Acad Sci U S A 2013; 110:9607-9612.
85. MacArthur DG, Balasubramanian S, Frankish A, et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science 2012; 335:823-828.
86. Cohen JC, Boerwinkle E, Mosley TH Jr, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272.
87. Nejentsev S, Walker N, Riches D, et al. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009; 324:387-389.
88. Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011; 43:1066-1073.
89. Raychaudhuri S, Iartchouk O, Chin K, et al. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat Genet 2011; 43:1232-1236.
90. Momozawa Y, Mni M, Nakamura K, et al. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet 2011; 43:43-47.
91. Jordan CT, Cao L, Roberson ED, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet 2012; 90:796-808.
92. Bonnefond A, Clement N, Fawcett K, et al. Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 2012; 44:297-301.
93. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154-156.
94. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37:161-165.
95. Kotowski IK, Pertsemlidis A, Luke A, et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006; 78:410-422.
96. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366:1108-1118.
97. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet 2012; 380:29-36.
98. Hunt KA, Mistry V, Bockett NA, et al. Negligible impact of rare autoimmunelocus coding-region variants on missing heritability. Nature 2013; 498:232- 235.